Uptake Medical

Uptake Medical

2216
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Uptake Medical is dedicated to transforming the treatment of severe pulmonary diseases through its proprietary vapor ablation platform. Its flagship InterVapor® System is commercially available in key international markets, generating revenue, while U.S. market access remains a pivotal strategic goal pending FDA approval. The company operates as a core subsidiary of Broncus Medical (HKEX: 2216), utilizing this structure for R&D, manufacturing, and commercial expansion across Asia, Europe, and Australia.

RespiratoryOncology

Technology Platform

Bronchoscopic Thermal Vapor Ablation (BTVA) platform delivering controlled heated water vapor via bronchoscope for precise tissue ablation in lung diseases.

Funding History

2
Total raised:$30M
Series B$20M
Series A$10M

Opportunities

FDA approval for severe emphysema would unlock the large, underserved U.S.
market.
The non-implant BTVA technology differentiates it from competitors and could address a broader patient population, including those with homogeneous disease.
Integration within Broncus provides global commercial and manufacturing leverage.

Risk Factors

Primary risk is failure to achieve positive results in the U.S.
pivotal trial or secure FDA approval.
Commercial success depends on overcoming entrenched competition and securing favorable reimbursement.
Execution is dependent on the financial and strategic health of parent company Broncus Medical.

Competitive Landscape

In emphysema, main competitor is Pulmonx (Zephyr Valve), an implanted device. Uptake's non-implant vapor ablation offers a differentiated mechanism avoiding valve-related complications. In lung cancer ablation, it faces numerous established thermal/mechanical modalities and must prove superior ease and efficacy.